Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The myth of the second remission of acute leukemia in the adult.

Blood - 14 Feb 2013

Forman Stephen J, Rowe Jacob M

Abstract excerpt

Although the majority of adult patients with both acute lymphoblastic leukemia and acute myelogenous leukemia achieve remission with upfront chemotherapy, many patients still suffer relapse. Often, the strategy is proposed of treating patients with relapsed leukemia into a second remission (CR2)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation
Share to Leukemia, Myeloid, Acute
Share to Neoplasm, Residual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Recurrence

Share to Remission Induction

Share to Survival Analysis

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 23243288
DOI: 10.1182/blood-2012-08-234492
PMCID: PMC3575753

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23243288-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The myth of the second remission of acute leukemia in the adult.PMID 23243288Read ↗

Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute LeukemiaSemantic proximity Read ↗

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.Semantic proximity Read ↗

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patientSemantic proximity Read ↗

Biology of post-transplant relapse: actionable features.Semantic proximity Read ↗

Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantationSemantic proximity Read ↗

AML evolution from preleukemia to leukemia and relapse.Semantic proximity Read ↗

Importance of measurable residual disease in the outcome of adults with acute lymphoblastic leukemia after allogeneic stem cell transplantation: Long follow-up analysis from a single transplant centerSemantic proximity Read ↗

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.Semantic proximity Read ↗

Allogeneic transplantation for AML with RUNX1::RUNX1T1 fusion: a time-dependent analysis in a retrospective studySemantic proximity Read ↗

Minimal residual disease in acute myeloid leukemia: coming of age.Semantic proximity Read ↗

Tracing the origins of relapse in acute myeloid leukaemia to stem cells.Semantic proximity Read ↗

The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.